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cADPR(cyclicADP-ribose)isauniversalCa
2+ mobilizingsecond
messenger.InT-cellscADPRisinvolvedinsustainedCa
2+ release
a n da l s oi nC a
2+ entry. Potential mechanisms for the latter include
either capacitative Ca
2+ entry, secondary to store depletion by
cADPR, or direct activation of the non-selective cation channel
TRPM2 (transient receptor potential cation channel, subfamily
melastatin, member 2). Here we characterize the molecular target
of the newly-described membrane-permeant cADPR agonist
8-Br-N
1-cIDPR (8-bromo-cyclic IDP-ribose). 8-Br-N
1-cIDPR
evoked Ca
2+ signalling in the human T-lymphoma cell line Jurkat
and in primary rat T-lymphocytes. Ca
2+ signalling induced by
8-Br-N
1-cIDPRconsistedofCa
2+ releaseandCa
2+ entry.Whereas
Ca
2+ release was sensitive to both the RyR (ryanodine receptor)
blockerRuRed(RutheniumRed)andthecADPRantagonist8-Br-
cADPR (8-bromo-cyclic ADP-ribose), Ca
2+ entry was inhibited
by the Ca
2+ entry blockers Gd
3+ (gadolinium ion) and SKF-
96365, as well as by 8-Br-cADPR. To unravel a potential role
for TRPM2 in sustained Ca
2+ e n t r ye v o k e db y8 - B r -N
1-cIDPR,
TRPM2 was overexpressed in HEK (human embryonic kidney)-
293 cells. However, though activation by H2O2 was enhanced
dramatically in those cells, Ca
2+ signalling induced by 8-Br-
N
1-cIDPR was almost unaffected. Similarly, direct analysis of
TRPM2 currents did not reveal activation or co-activation
of TRPM2 by 8-Br-N
1-cIDPR. In summary, the sensitivity to
the Ca
2+ entry blockers Gd
3+ and SKF-96365 is in favour of the
concept of capacitative Ca
2+ entry, secondary to store depletion
by 8-Br-N
1-cIDPR. Taken together, 8-Br-N
1-cIDPR appears to
be the ﬁrst cADPR agonist affecting Ca
2+ release and secondary
Ca
2+ entry, but without effect on TRPM2.
Keywords:Ca
2+ entry,Ca
2+ release,cyclicADP-ribose(cADPR),
cyclic ADP-ribose (cADPR) analogue, T-cell activation, transient
receptor potential cation channel, subfamily melastatin, member
2( T R P M 2 ) .
INTRODUCTION
cADPR(cyclicADP-ribose)isauniversalCa
2+ mobilizingsecond
messenger (reviewed in [1–4]). Receptor-mediated formation
has been demonstrated for several cell types and multiple
ligands/receptors (reviewed in [1–4]). Formation of cADPR
in eukaryotic cells proceeds via ADP-ribosyl cyclases, among
whichthemultifunctionalectoenzymeCD38isbestcharacterized
(reviewed in [5]). Originally, cADPR was discovered as the
endogenousnucleotidethatreleasesCa
2+ fromintracellularstores
of sea urchin eggs [6,7]. However, involvement of cADPR in
Ca
2+ entry was discovered approx. ten years later in human
T-lymphocytes [8].
Ca
2+ entry in T-lymphocytes is a process essential for
proliferation, as a continuously elevated level of the free
cytosolic and nuclear Ca
2+ concentration ([Ca
2+]i) is necessary
for continuous activation of the Ca
2+ and calmodulin-dependent
protein phosphatase calcineurin [9]. The latter dephosphorylates
NF-AT (nuclear factor of activated T-cells) thereby allowing
translocation of NF-AT into the nucleus [10,11].
As a mechanism for Ca
2+ entry in T-cells, capacitative Ca
2+
entry [12] has long been postulated (reviewed in [13]). With
the discovery of key proteins involved, e.g. Orai1/CRACM1
(calcium release-activated calcium modulator 1) [14,15] and
Stim1 (stromal interaction molecule 1) [16], it became clear
that Stim1, by sensing decreasing luminal Ca
2+ concentration
upon store depletion, would activate Ca
2+ entry involving
Orai1/CRACM1 as channels, or as part of a larger channel
complex. In T-lymphocytes we have demonstrated a crucial role
for cADPR in Ca
2+ entry, as blockade of cADPR action resulted
in reduced Ca
2+ signalling, especially in the sustained phase [17].
Importantly,subsequentsignallingevents,e.g.CD25andMHC-II
(myosin heavy chain-II) expression, as well as proliferation, were
likewise inhibited by cADPR antagonism [17].
H e r e ,w ec h a r a c t e r i z et h eC a
2+ entry mechanism activated by
the novel cADPR agonist, 8-Br-N
1-cIDPR (8-bromo-cyclic IDP-
ribose)[18].TheadvantagesofthismoleculeovernaturalcADPR
are its ability to permeate membranes and its metabolic stability.
Indeed, we recently showed that substitution of the amino/imino-
group at C
6 by an oxo-group, thus converting the bond between
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N
1 and C
1   at the northern ribose into part of a much more
chemically stable amide system, produces a compound that is
also biologically stable [18].
EXPERIMENTAL
Drugs and materials
8-Br-NHD (8-bromo-nicotinamide hypoxanthine dinucleotide)
and cADPR were obtained from Biolog. 8-Br-N
1-cIDPR was
either synthesized and puriﬁed as described below (see also
Figure 1) or obtained from Biolog. ADP-ribosyl cyclase
from Aplysia californica, 8-Br-cADPR and GdCl3 were from
Sigma–Aldrich. RuRed (Ruthenium Red), SKF-96365, TCA
(trichloroacetic acid), diethyl ether, methanol (LiChrosolv) and
TFA (triﬂuoroacetic acid) were from Merck Chemicals. Rat anti-
CD3 antibody, goat anti-mouse IgM and Lipofectamine
TM 2000
were obtained from Invitrogen. Q-Sepharose Fast Flow and G10
Sephadex were obtained from Amersham Bioscience. FuGENE 6
was from Roche Applied Science. All other chemicals used were
of the highest purity grade and purchased from Merck Chemicals,
Fluka or Sigma–Aldrich. Culture medium reagents were supplied
by Sigma–Aldrich, Invitrogen or Biochrom.
Cell culture
Jurkat T-lymphocytes (subclone JMP) were cultured as described
previously in [19] at 37◦C in the presence of 5% CO2 in
RPMI 1640 medium containing Glutamax I and Hepes (25 mM)
and supplemented with 7.5% (v/v) NCS (newborn calf serum),
100 units/ml penicillin and 100 μg/ml streptomycin.
MBP (myelin basic protein)-speciﬁc T-cell clones were
established from lymph node preparations of pre-immunized
Lewis rats. Stimulation, expansion and culture of speciﬁc rat
T-cells were conducted under conditions described in [20].
For determination of Ca
2+ signalling, frozen rat T-cells were
thawed und cultured in DMEM (Dulbecco’s modiﬁed Eagle’s
medium)withGlutamaxI,4.5 g/lglucose,100 units/mlpenicillin,
100 μg/ml streptomycin, 1 mM sodium pyruvate, 10% (v/v)
horse serum, 0.004% (v/v) 2-mercaptoethanol, 1% (v/v) non-
essential amino acids and 0.04 g/l asparagine at 37◦Ci nt h e
presence of 10% CO2. Resting state T-cells were used in all
experiments.
HEK (human embryonic kidney)-293 cells were cultured at
37◦C in the presence of 5% CO2 in DMEM medium containing
Glutamax I and supplemented with 10% (v/v) FBS (fetal bovine
serum), 100 units/ml penicillin and 100 μg/ml streptomycin.
Synthesis and puriﬁcation of 8-Br-N1-cIDPR
8-Br-N
1-cIDPR was synthesized as described previously in
[21]. 8-Br-NHD (100 μmol) was incubated with 40 μg Aplysia
californicaADP-ribosylcyclasein25 mMHepes,pH 7.4,for15 h
at room temperature (24◦C) under continuous stirring in the dark.
ADP-ribosyl cyclase was removed by stepwise centrifugation for
1–2 h, at 4000 g and 4◦C, by use of centrifugal ﬁlter devices
type Centriprep YM-10 (10 kDa cut-off, Millipore). Synthesis
of 8-Br-N
1-cIDPR was conﬁrmed by RP (reverse-phase)-HPLC.
Puriﬁcation was carried out as previously described in [21] or by
anion-exchange chromatography and gel ﬁltration to remove the
by-products 8-Br-IDPR and nicotinamide. For anion-exchange
chromatography, Q-Sepharose Fast Flow was washed four times
with water, four times with 500 mM NaCl and ﬁve times with
puriﬁed water. Q-Sepharose Fast Flow (0.5 ml) was packed in
plastic ﬁltration tubes (Supelco) and washed with 10 ml of
puriﬁed water. The aqueous solution of 8-Br-N
1-cIDPR was
diluted 5-fold with puriﬁed water, to reduce ionic strength,
and applied to the column in 3 ml aliquots. The column was
washed twice with 5 ml of puriﬁed water. Elution of 8-Br-
N
1-cIDPR was carried out by subsequent addition of 1.5 ml
of NaCl solution at 20, 40, 60, 80, 100, 120, 140, 160, 180,
200 and 250 mM. The eluates were collected and analysed by
RP-HPLC. Eluates that contained only 8-Br-N
1-cIDPR (40–
100 mM NaCl) were combined. Salt was removed form the
puriﬁed 8-Br-N
1-cIDPR by gel ﬁltration on Sephadex G10.
For gel ﬁltration, 30 g of Sephadex G10 was suspended in
100 ml of water, heated for 1 h at 90◦C and washed 4 times
with water. A suspension with 75% (w/v) Sephadex G10 was
prepared, degassed, packed in a glass column (1.5 cm×30 cm)
and compacted for 16 h by gravity ﬂow of water. The solution of
8-Br-N
1-cIDPR was chromatographed with water as eluent.
Eluates were collected in a volume of 1–5 ml, analysed by
RP-HPLC, combined and freeze-dried. Final characterization of
purity and identity was done on RP-HPLC (see Figure 1).
Determination of membrane permeability of 8-Br-N1-cIDPR
Jurkat T-cells (∼2×10
8–2.5×10
8) were harvested by
centrifugation (550 g for 5 min at 4◦C), washed once with
buffer A (containing 20 mM Hepes, pH 7.4, 140 mM NaCl,
5m MK C l ,1m MM g S O 4, 1 mM CaCl2,1m MN a H 2PO4 and
5.5 mM glucose), resuspended in 1 ml of buffer A and were kept
at room temperature for 10 min. 8-Br-N
1-cIDPR (3 μmol) was
added and cells were incubated for 5 min at room temperature,
placed on an ice-salt bath for 3 min, harvested by centrifugation
(550 g)a t4 ◦C and washed once with 5 ml of ice cold buffer
A. Determination of membrane permeability of 8-Br-N
1-cIDPR
was performed in a similar way, as previously described
for endogenous ADPR in [22]. Brieﬂy, cells were lysed in
TCA, and cell debris was removed. The samples were divided
in half, and to one half 50 nmol 8-Br-N
1-cIDPR was added, to
identify the 8-Br-N
1-cIDPR peak by HPLC and to calculate the
recoveryduringtheextraction.Proteinprecipitateswereremoved,
and the supernatants were neutralized by extraction with diethyl
ether. The samples were then puriﬁed by solid-phase extraction.
For solid-phase extraction plastic ﬁltration tubes (Supelco)
were packed with Q-Sepharose Fast Flow and were cleaned
in place with 150 mM TFA. Columns were equilibrated with
10 mM Tris/HCl, pH 8.0. The cellular extracts were diluted
with 10 mM Tris/HCl, pH 8.0 and applied to the columns. The
columns were washed with 10 mM Tris/HCl, pH 8.0, followed by
600 μl of 40 mM TFA. For the elution of 8-Br-N
1-cIDPR, 1 ml of
a 80 mM TFA solution was applied. Samples were neutralized by
NaOH, ﬁltered through 0.2 μm ﬁlters (Sartorius) and analysed
byRP-HPLCasdescribedbelow.Asacontrolthenon-brominated
dinucleotideNHD(nicotinamidehypoxanthinedinucleotide)was
used in parallel.
RP-HPLC
RP-HPLC analysis of nucleotides was performed on a 250 mm×
4.6 mm Multohyp BDS-C18 5μ column (CS Chromatographie
Service) equipped with a 17 mm×4.6 mm guard column
or with a 4.0 mm×3.0 mm guard cartridge containing a
C18 ODS ﬁlter element (Phenomenex). The separation was
performed as described previously in [23] at a ﬂow rate
of 1 ml/min with RP-HPLC buffer (20 mM KH2PO4,5 m M
tetrabutylammonium dihydrogen phosphate, pH 6) containing
increasing amounts of methanol. The gradient used for separation
was usually, 0 min (6.5% methanol), 3.5 min (7.5% methanol),
5.5 min (16% methanol), 8 min (25% methanol), 18 min
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(6.5% methanol) and 27 min (6.5% methanol). For separation
of 8-Br-N
1-cIDPR in cell extracts the following gradient
was used: 0 min (6.5% methanol), 1.5 min (6.5% meth-
anol), 3.5 min (7.5% methanol), 5.5 min (16% methanol),
6.5 min (16% methanol), 14 min (32.5% methanol), 16 min
(32.5% methanol), 18 min (6.5% methanol) and 27 min
(6.5% methanol). Nucleotides were detected using an UV de-
tector(HPLCdetector432,KontronInstruments)oraDAD(photo
diodearraydetector1200series,AgilentTechnologies)at250 nm
and 260 nm for hypoxanthine or at 270 nm for adenine-based
nucleotidesrespectively.Integrationofpeakswasperformedwith
the data-acquisition system MT2 from Kontron Instruments or
with the Rev. B.02.01 ChemStation from Agilent technologies.
Quantiﬁcation was performed with external standards.
Transient transfection of HEK-293 cells
AcDNAcontainingthetotalORF(openreadingframe)ofhuman
TRPM2 (transient receptor potential cation channel, subfamily
melastatin, member 2) was ampliﬁed from human RNA by one-
step RT (reverse transcription)–PCR using the Titan One-Tube
RT-PCR kit (Roche) according to the manufacturer’s instructions
(forwardprimerincludingEcoRIsite,5
 -GGAATTCATGGAGC-
CCTCAGCCCTG-3
 ; reverse primer including a SalI site, 5
 -TA-
CTGTCGACTCAGTAGTGAGCCCC-3
 ). The resulting ampli-
con was cloned into the EcoRI and SalI sites of the multiple clon-
ing site of pIRES2-EGFP (enhanced green ﬂuorescent protein)
(Clontech). This vector was termed pIRES2-EGFP-TRPM2.
For transfection, HEK-293 cells were seeded in 35 mm dishes,
cultured to a density of 50–80% of conﬂuency and were
transfected by addition of transfection mixture consisting of
100 μlofOptiMEM,3 μlofFuGENEor3μlofLipofectamine
TM
2000 and 1 μg of plasmid DNA (pIRES2-EGFP or pIRES2-
EGFP-TRPM2) to the cells. For transfection with FuGENE,
transfection mixture was added directly to the cell culture
medium, whereas transfection with Lipofectamine
TM 2000
was carried out in OptiMEM. For Ca
2+-imaging experiments,
transfected cells were seeded in 8-well slides (ibidi) coated with
poly-L-lysine (70–150 kDa) at a low cell density.
Ratiometric Ca2+ imaging
Jurkat T-cells were loaded with Fura-2AM (Fura-2-
acetoxymethyl ester) as described in [19] and kept in the
dark at room temperature until use. Primary rat T-cells were
loaded with 12 μM Fura-2AM and 2 mM probenicid for 30 min
at 37◦C in the dark, washed twice with buffer A and kept in the
dark at 15–18◦C until use. HEK-293 cells were loaded in 8-well
slides with 4 μM Fura-2AM in HEK-293 cell medium for 30 min
at 37◦C in the dark and washed twice with buffer A.
For Ca
2+ imaging of Jurkat T-cells or rat T-cells thin glass
coverslips (0.1 mm) were coated ﬁrst with BSA (5 mg/ml) and
subsequentlywithpoly-L-lysine(0.06–0.1 mg/ml).Silicongrease
was used to seal small chamber slides, consisting of a rubber
O-ring, on the glass coverslip. Then, 40–60 μlo fb u f f e rAa n d
40 μl of T-cell suspension (∼1×10
6–2×10
6 cells/ml) in the
same buffer were added into the small chamber. Where the
calcium free/calcium re-addition protocol was used, 0.2×10
6
Jurkat T-cells were washed twice in nominal Ca
2+-free buffer
A and added to the small chamber. The time the cells were
held under Ca
2+-free conditions was kept as short as possible
to avoid emptying of the ER (endoplasmic reticulum) Ca
2+ pool;
such emptying due to prolonged exposure to Ca
2+ free conditions
resulted in very low or undetectable Ca
2+ signals upon cADPR
microinjections in a previous study [8]. The loaded coverslip
or 8-well slide was mounted on the stage of a Leica DMIRE2
ﬂuorescencemicroscope.InsomeexperimentsJurkatT-cellswere
preincubated with GdCl3 (25 μM), SKF-96365 (30 μM) or 8-
Br-cADPR (500 μM) in buffer A. In experiments with GdCl3,
Na2HPO4 was not included in buffer A, to prevent precipitation
of GdPO4.
Ratiometric Ca
2+ imaging was performed as described in
[24]. We used an Improvision imaging system, built around the
Leicamicroscope,at40-or100-timesmagniﬁcation.Illumination
at 340 and 380 nm was carried out using a monochromator
system (Polychrom IV, TILL Photonics). Images were taken
with a gray-scale charge-coupled device camera (type C 4742–
95–12ER; Hamamatsu) operated in 8-bit mode. The spatial
resolution was 512×640 pixels. Camera exposure times were
12–30 ms (at 340 nm) and 4–10 ms (at 380 nm) at a 3:1 ratio.
The acquisition rate was adjusted to ∼14 ratios per minute.
Raw data images were stored on a hard disk and ratio images
(340/380 nm) were constructed pixel by pixel. Confocal Ca
2+
images were obtained by off-line deconvolution using the volume
deconvolution module and a no-neighbour algorithm in the
Openlab software (Improvision) as described recently for 3T3
ﬁbroblasts in [25]. The deconvoluted images were used to
construct ratio images (340/380 nm) pixel by pixel. Finally,
ratio values were converted into Ca
2+ concentrations by external
calibration as described in [24]. Data processing was performed
using Openlab software, version 3.0.8 or 1.7.8.
Microinjection
Microinjections were carried out as described in [8]. We used
an Eppendorf system (transjector type 5171, micromanipulator
type 5246) or Femtojet (Eppendorf AG) with Femtotips I or
II as pipettes. 8-Br-N
1-cIDPR or cADPR were diluted to their
ﬁnal concentration in intracellular buffer (20 mM Hepes, pH 7.2,
110 mM KCl, 10 mM NaCl), ﬁltered (0.2 μm) and centrifuged
(15700 g for 10 min at 4◦C) before use. Injections were made
using the semiautomatic mode of the system with the following
instrumental settings: injection pressure 6–8 kPa, compensatory
pressure2.5–4kPa,injectiontime0.5sandvelocityofthepipette
700 μm/s.
Electrophysiology
Membrane currents were recorded in the whole cell conﬁguration
of the patch clamp technique as described in [26]. An EPC10
USB patch clamp ampliﬁer was used in conjunction with
the PULSE stimulation and data acquisition software (HEKA
Elektronik). Data were sampled at 5 kHz and compensated for
both fast and slow capacity transients. Series resistance was
compensated by 70%. All experiments were performed at room
temperature with Jurkat T-cells attached to tissue culture dishes
before the experiment. The pipette solution contained 10 mM
Hepes, pH 7.2 (adjusted with KOH), 140 mM KCl, 1 mM MgCl2
and 8 mM NaCl. In some experiments, the pipette solution
additionallycontainedADPR(30,100,300or1000 μM),cADPR
(30, 100, 300 or 1000 μM), 8-Br-N
1-cIDPR (300 μM), ADPR
(30 μM) plus either cADPR (5 μM or 100 μM) or 8-Br-N
1-
cIDPR (300 μM). The external solution contained 10 mM Hepes,
pH 7.4 (adjusted with NaOH), 140 mM NaCl, 2 mM MgCl2,
2m MC a C l 2, 5 mM KCl and 5 mM glucose. The cells were held
at −60 mV and current–voltage relations were obtained every 5 s
using 250 ms voltage ramps from −85 to −65 mV.
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Figure 1 Synthesis of 8-Br-N1-cIDPR
(a) RP-HPLC of standard 1, 8-Br-NHD and 8-Br-N1-cIDPR (8-Br-cIDPR). (b) RP-HPLC of standard 2, nicotinamide (NicAmid), 8-Br-NHD and 8-Br-IDPR. 8-Br-IDPR was synthesized by incubation
of 8-Br-NHD with NADase of Neurospora crassa. 1 mM 8-Br-NHD was incubated with 1 μg/μl ADP-ribosyl cyclase of A. californica in 25mM Hepes, pH7.4, for 15h at room temperature. Aliquots
were taken at (c)0ha n d( d) 15h and analysed by RP-HPLC. (e) RP-HPLC of puriﬁed 8-Br-N1-cIDPR.
RESULTS
8-Br-N
1-cIDPR was prepared by quantitative conversion of 8-Br-
NHD into 8-Br-N
1-cIDPR using A. californica ADP-ribosyl
cyclase (Figure 1). Comparison of the products after a 15 h
incubation period with standards clearly showed that the main
product was 8-Br-N
1-cIDPR. However, a small portion of
8-Br-NHD was converted into the linear product 8-Br-IDPR
(Figure 1d). This small contamination of 8-Br-IDPR was
quantitativelyremovedbyanion-exchangechromatographyusing
Sepharose Q Fast Flow followed by desalting of puriﬁed 8-Br-
N
1-cIDPR on Sephadex 10 Fast Flow. The ﬁnal product showed
a purity of almost 100% on HPLC (Figure 1e).
Although we had reported previously [21] that 8-Br-N
1-cIDPR
ismembrane-permeantweinitiallyassessedthebiologicalactivity
of 8-Br-N
1-cIDPR in combined microinjection and Ca
2+ imaging
experiments. This was in order to obtain a proper concentration–
responserelationshipwithoutanypotentialadditionaleffects,due
to membrane permeancy and/or pumping out of the compound by
multiple drug resistance transporters. Whereas microinjection of
intracellular buffer into intact Fura-2AM-loaded Jurkat T-cells
had little effect (Figure 2a), the natural cADPR showed a robust
response when microinjected at 100 μM (Figure 2b). It must be
noted here that in such microinjection experiments only ∼1–
1.5% of the cell volume is injected [8], resulting in an effective
intracellular concentration far below the pipette concentration. At
100 μM, 8-Br-N
1-cIDPR evoked Ca
2+ signalling only in some
cells (Figure 2c), whereas at pipette concentrations of 1m M
8-Br-N
1-cIDPR, robust Ca
2+ responses were recorded, consisting
of a rapid and high Ca
2+ peak within tens of seconds followed by
a lower, but sustained plateau phase (Figure 2d–2f). The effect
was saturable and showed an EC50 of about 300 μM (Figure 2g).
Importantly, the 8-substitution with bromine in 8-Br-
N
1-cIDPR resulted in a membrane-permeant molecule, as
already determined in initial experiments [21]. To check the
membrane permeabilty of 8-Br-N
1-cIDPR directly, Jurkat
T-cells were incubated with 8-Br-N
1-cIDPR for 5 min, then
cellular nucleotides were extracted with TCA and crude cell
extracts were puriﬁed by solid-phase extraction and analysed
byRP-HPLC(Figure3)inasimilarwayasdescribedforADPRin
Figure 2 Microinjection of 8-Br-N1-cIDPR in intact Jurkat T-cells
Jurkat T-cells were loaded with Fura-2AM and subjected to combined Ca2+ imaging and
microinjection. Time points of microinjection are indicated by arrows. Cells were microinjected
(a) with intracellular buffer (n=21) or (b) or 100μM cADPR, (n=20) as controls or with
(c)0 . 1 m M( n=6), (d)1 m M( n=7), (e)1 0 m M( n=10) or (f) 100mM (n=5)
8-Br-N1-cIDPR. (g) Concentration–response curve of 8-Br-N1-cIDPR. Results are shown as
means+ −S.E.M. (n=5–21) of single tracings from time points 50–100s (the Ca2+ peak).
*, P <0.01; **, P <0.001 (t test).
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Figure 3 Membrane permeability of 8-Br-N1-cIDPR
Jurkat T-cells were incubated with 3 mM 8-Br-N1-cIDPR for 5min at room temperature. Cellular nucleotides were extracted with TCA. Crude cell extracts were puriﬁed by solid-phase extraction
and analysed by RP-HPLC. (a) Representative RP-HPLC analysis of absorbed 8-Br-N1-cIDPR in Jurkat T-cells is shown (black line). (b) Magniﬁcation of the trace shown in (a). The peak of
8-Br-N1-cIDPR is indicated by an arrow. As a control, cell extracts of cells not incubated with 8-Br-N1-cIDPR were analysed by HPLC (grey line). Jurkat T-cells incubated with 8-Br-N1-cIDPR took
up 0.16 fmol per cell with a recovery of about 88%. Results are means (n=2).
Figure 4 Extracellular addition of 8-Br-N1-cIDPR evoked Ca2+ signalling in intact Jurkat T-cells
Jurkat T-cells were loaded with Fura-2AM and subjected to Ca2+ imaging. The time points of addition of (a) buffer, (b)1m MN1-cIDPR and (c)1m M8 - B r - N1-cIDPR are indicated by arrows.
Characteristic tracings from a representative experiment are shown. (d) Concentration–response curve of 8-Br-N1-cIDPR. Results represent means+ −S.E.M. (n=21–109) of single tracings from
time points 100–400s (of the 8-Br-N1-cIDPR mediated Ca2+ peak). *P < 0.01 and **P <0.001.
[22]. In Jurkat T-cells incubated with 8-Br-N
1-cIDPR a
cellular uptake of 0.16 fmol/cell was measured (Figure 3). In
contrast, cells incubated with the non-brominated dinucleotide
NHD did not take up this molecule, indicating that bromination
is a prerequisite for membrane permeancy (results not shown). In
separate experiments, we checked that NHD was not metabolized
in the time period of the uptake experiments.
Addition of membrane permeant 8-Br-N
1-cIDPR to intact
Jurkat T-cells induced a dose-dependent Ca
2+ signal (Figure 4).
At concentrations 1m M ,8 - B r - N
1-cIDPR induced a rapid Ca
2+
response in these cells consisting of a Ca
2+ peak and a small but
sustained plateau phase (Figure 4c), whereas no Ca
2+ signal was
mediated by addition of the non-brominated analogue N
1-cIDPR
(Figure 4b) or buffer (Figure 4a). As 8-Br-N
1-cIDPR at 1 mM
induced robust and signiﬁcant Ca
2+ signalling, this extracellular
concentration was chosen for most further experiments.
To also test the effect of 8-Br-N
1-cIDPR on primary
T-cells, rat MBP-speciﬁc T-cells were loaded with Fura-2AM
and subjected to Ca
2+ imaging (Figure 5). Buffer was added
as a negative control and cells were stimulated via the T-cell
receptor/CD3 complex (using anti-CD3 antibody, followed by
cross-linking IgM) as a positive control (Figures 5a and 5b).
Although anti-CD3 antibody alone resulted in a robust Ca
2+
signal, cross-linking of the primary antibody on the surface of the
cells further enhanced the stimulation (Figure 5b). Addition of
8-Br-N
1-cIDPR resulted in Ca
2+ signals with different kinetics
and amplitudes with regard to individual cells (Figure 5c).
When stimulation with 8-Br-N
1-cIDPR was compared with
T-cell receptor/CD3 stimulation, similar individual differences
in kinetics were observed (compare Figures 5b and 5c), but
peak amplitudes were signiﬁcantly lower for 8-Br-N
1-cIDPR
(Figure 5d). This difference is not unexpected, as in the ﬁrst
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Figure 5 Extracellular addition of 8-Br-N1-cIDPR evoked Ca2+ signalling in primary rat T-cells
RatT-cellswereloadedwithFura-2AMandsubjectedtoCa2+ imaging.Thetimepointsofadditionof(a)buffer,(b)anti-CD3followedbyacross-linkingIgM(40μg/mland10μg/ml)and(c)1mM
8-Br-N1-cIDPR are indicated by arrows. Characteristic tracings from a representative experiment are shown. (d) Combined results representing means+ −S.E.M (n=186–241) of single tracings
from time points 100–400s (the Ca2+ peak). **, P <0.001 (t test).
Figure 6 8-Br-N1-cIDPR activated both Ca2+ release and Ca2+ entry in intact Jurkat T-cells
Jurkat T-cells were loaded with Fura-2AM and subjected to Ca2+ imaging. (a) Cells were kept in a nominally Ca2+ free buffer in the ﬁrst part of experiment and 8-Br-N1-cIDPR was added as
indicated. Then, CaCl2 was re-added. (b) Buffer was added instead of 8-Br-N1-cIDPR as a control. The time points of addition of buffer, 1mM 8-Br-N1-cIDPR or 1mM Ca2+ are indicated by arrows.
Characteristic tracings from representative experiments are shown. (c) Combined data representing means+ −S.E.M. (n=362–404) of single tracings from time points 100–200s (8-Br-N1-cIDPR
mediated Ca2+ release-peak) or 300–450s (8-Br-N1-cIDPR mediated Ca2+ entry-peak). **, P <0.001 (t test).
10 min of T-cell activation at least three Ca
2+ release systems,
NAADP (nicotinic acid adenine dinucleotide phosphate), IP3
(D-myo-inositol-1,4,5-trisphosphate) and cADPR are involved
(reviewed in [3,27]). However, 8-Br-N
1-cIDPR mimicked the
second phase of T-cell receptor/CD3-mediated Ca
2+ signalling,
once again underpinning the essential role of cADPR in sustained
Ca
2+ signalling in T-cells.
cADPR has been shown not only to act on intracellular Ca
2+
release via RyR (ryanodine receptor) [17], but also to sensitize
the TRPM2 cation channel for its ligand ADPR [28,29]. To
analysethemechanismofthecADPRanalogue8-Br-N
1-cIDPRin
more detail, a Ca
2+-free–Ca
2+ reintroduction protocol was used
to separate potential Ca
2+ release and Ca
2+ e n t r ye v o k e db y8 -
Br-N
1-cIDPR (Figure 6). Under Ca
2+-free conditions, a robust
Ca
2+ release upon addition of 8-Br-N
1-cIDPR was observed
(Figures 6a and 6b). Re-addition of extracellular Ca
2+ resulted
in a huge Ca
2+ entry overshoot followed by a small sustained
plateau phase (Figures 6a and 6b). These results suggest that 8-
Br-N
1-cIDPR activates both Ca
2+ release and Ca
2+ entry.
Secondly, co-microinjections of 8-Br-N
1-cIDPR with RuRed
were carried out (Figure 7). RuRed largely reduced the initial
Ca
2+ peak (Figures 7c and 7d) indicating that this initial peak
mainly depends on RyR.
Taken together, we showed that 8-Br-N
1-cIDPR behaved
similarly to cADPR. In the next sets of experiments we aimed
to analyse in more detail the Ca
2+ entry pathway activated by
8-Br-N
1-cIDPR by using inhibitors of Ca
2+ entry, GdCl3 and
SKF-96365 [8,30,31]. In both cases robust Ca
2+ release was
observed under Ca
2+-free conditions, whereas Ca
2+ entry was in-
hibited (Figures 8c, 8d, 8g and 8h). Interestingly, preincubation
with Gd
3+ increased Ca
2+ release induced by 8-Br-N
1-cIDPR
signiﬁcantly (Figure 8d). A potential explanation for this effect
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Figure 7 Effect of RuRed on 8-Br-N1-cIDPR mediated Ca2+ signalling in intact Jurkat T-cells
Jurkat T-cells were loaded with Fura-2AM and subjected to combined Ca2+ imaging and microinjections. Time points of microinjection are indicated by arrows. Cells were microinjected with
(a) intracellular buffer (n=26), (b)1m M8 - B r - N1-cIDPR (n=21) or (c)am i x t u r eo f1 0μM RuRed and 1 mM 8-Br-N1-cIDPR (n=20). (d) Combined results representing means+ −S.E.M. of
single tracings from time points 50–150s (the Ca2+ peak). **, P < 0.001 (t test). ns, not signiﬁcant.
is the sensitivity of the plasma membrane Ca
2+-ATPase to Gd
3+
[32]; inhibition of Ca
2+ extrusion in the absence of extracellular
Ca
2+ would in fact result in an apparent increase in [Ca
2+]i.
In the presence of the cADPR antagonist 8-Br-cADPR, Ca
2+
release was partially, but not signiﬁcantly inhibited (Figures 8k
and8l).Interestingly,therewasfullinhibitionofCa
2+ entryunder
such conditions. It is probable that the incomplete inhibition
of Ca
2+ release is due to the partial antagonist character of
8-Br-cADPR [33]. As discussed above for Ca
2+ entry, at least
two mechanisms may be involved, either the diminished Ca
2+
release resulted in inhibition of capacitative Ca
2+ entry via
Orai1/CRACM1 channels [34], or direct activation of Ca
2+ entry
by 8-Br-N
1-cIDPR was inhibited by 8-Br-cADPR. As Kolisek
et al. [28] previously showed that cADPR, together with ADPR,
activates the unspeciﬁc cation channel TRPM2, we used HEK-
293 cells transiently overexpressing TRPM2 or EGFP (as a
negative control) for further experiments. As positive control,
Ca
2+ signalling induced by H2O2 was used, as it was previously
shown that H2O2 increased the open probability TRPM2 [28,35].
These results were conﬁrmed in experiments for the present
study (Figures 9a and 9d). In contrast, statistically signiﬁcant
effects between TRPM2-overexpressing cells and controls were
not obtained when 8-Br-N
1-cIDPR was used as activator of
Ca
2+ signalling up to extracellular concentrations of 10 mM
(Figures 9b, 9e and 9g).
In the next series of experiments direct activation of
endogenouslyexpressedTRPM2inJurkatT-cellswasanalysedby
patch-clamp recordings in the whole-cell conﬁguration. Infusion
of ADPR (300 μM) at a membrane potential of −80 mV evoked
a marked inward current (Figure 10a) characterized by an almost
linearIV-relationship(Figure10b)andasaturableconcentration–
response relationship with an EC50 of 133 μM (Figure 10c).
Infusion of cADPR alone did not activate the TRPM2 current,
except for a minor effect at 1 mM cADPR pipette concentration
(Figure 10c). However, due to the small contamination of 4%
ADPR (Figure 10e), amounting to 40 μM ADPR, in the pipette,
it is probable that ADPR contamination, and not the cADPR in
thepipette,inducedthecurrent.Comparingtheamplitudesevoked
by 30 μM ADPR and 1 mM cADPR (containing 40 μM ADPR)
further substantiates this conclusion (Figure 10c). Infusion of
a combination of a low concentration of ADPR (30 μM) plus
cADPR had a small modulatory effect when 100 μM cADPR
was used (Figure 10d), indicating a co-modulatory role of
cADPR on TRPM2, activated by low concentrations of ADPR,
as described in [35]. However, 8-Br-N
1-cIDPR neither activated
TRPM2 alone (Figure 10c) nor in combination with low ADPR
(Figure 10d).
DISCUSSION
In this report we demonstrate that the membrane-permeant
cADPR agonist 8-Br-N
1-cIDPR evokes Ca
2+ signalling in both
the T-lymphoma cell line Jurkat and in primary T-cells. Ca
2+
signalling induced by 8-Br-N
1-cIDPR consisted of both
Ca
2+ release and Ca
2+ entry. Whereas Ca
2+ release was sensitive
to both the RyR blocker RuRed and the cADPR antagonist 8-Br-
cADPR, Ca
2+ entry was inhibited by the non-speciﬁc Ca
2+ entry
blockers Gd
3+ and SKF-96365, as well as by 8-Br-cADPR [10].
Activation of TRPM2 by 8-Br-N
1-cIDPR was neither observed in
heterologously expressed TRPM2 in HEK-293 cells activated by
H2O2, nor in endogenously expressed TRPM2 in Jurkat T-cells.
Furthermore, 8-Br-N
1-cIDPR did not co-activate TRPM2 when
infused together with a low concentration of ADPR.
Stimulation of T-cell Ca
2+ signalling via the T-cell
receptor/CD3 complex involves the subsequent formation of at
least three second messengers. Within a few seconds NAADP
is produced, peaking after around 10–20 s and returning to the
baseline level rapidly [36]. NAADP serves as the initial Ca
2+
triggerto‘ignite’theCa
2+ signallingsystemofT-cells(forreview
see [37]). Next, IP3 is produced transiently, and initiates global
Ca
2+ signalling within the ﬁrst 15–20 min of T-cell activation
[38]. In contrast, cADPR is formed more slowly and continues
to release Ca
2+ from internal stores as IP3 levels fall [17].
Thus sustained and elevated cADPR levels and sustained Ca
2+
signallingbycADPRareessentialcomponentsofT-cellactivation
c   The Authors Journal compilation c   2009 Biochemical Society © 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.146 T. Kirchberger and others
Figure 8 Effect of Gd3+, SKF-96365 and 8-Br-cADPR on Ca2+ release and Ca2+ entry mediated by 8-Br-N1-cIDPR in intact Jurkat T-cells
Jurkat T-cells were loaded with Fura-2 and subjected to Ca2+ imaging. (a), (e)a n d( i) show negative controls. Cells were kept in a nominal Ca2+ free buffer in the ﬁrst part of the experiment and
buffer was added as indicated and then CaCl2 was re-added. (b)( f)a n d( j) show positive controls. 8-Br-N1-cIDPR was added instead of buffer. Cells were preincubated with (c)1 0μMG d 3+,
(g)3 0μM SKF-96365 or (k) 500μM 8-Br-cADPR. Time points of addition of buffer, 1 mM 8-Br-N1-cIDPR or 1mM Ca2+ are indicated by arrows. Characteristic tracings from a representative
experiment are shown. (d), (h)a n d( i) Combined data representing means+ −S.E.M. (n=86–138) of single tracings from time points 100–200s (8-Br-N1-cIDPR mediated Ca2+ release-peak),
300–450s (8-Br-N1-cIDPR mediated Ca2+ entry-peak). *, P < 0.01; **, P < 0.001 (t test).
[17].AstheintracellularCa
2+ storesofT-cellsarelowincapacity,
sustained Ca
2+ signalling is only possible by recruitment of Ca
2+
entry.Intheory,atleasttwomechanismsforCa
2+ entryevokedby
the sustained high cADPR levels are possible: either capacitative
Ca
2+ entry [12] via Orai1/CRACM1 channels [14,15] is activated
by reduced store loading secondary to cADPR action, or cADPR
acts as a co-activator of TRPM2 as described previously [28,29].
As described for a number of membrane-permeant cADPR
agonists {e.g. N
1-ethoxymethyl-cIDPR [39], N
1-[(phosphoryl-
O-ethoxy)-methyl]-N
9-[(phosphoryl-O-ethoxy)-methyl]-hypox-
anthine-cyclic pyrophosphate [40], 2
 ,3
 -dideoxy-didehydro-
cyclic ADP-carbocyclic ribose [41], 8-phenyl-cIDPR [42] and
N
1-[(5
 -O-phosphoryl)ethoxyethyl]-5-O-phosphoryladenosine 5
 ,
5
 -cyclic pyrophosphate [43]} 8-Br-N
1-cIDPR essentially
mimicks the cADPR branch of T-cell Ca
2+ signalling. However,
fornoneofthesecADPRagonistanalogueshasthemechanismof
Ca
2+ entrybeenelucidated.As8-Br-NHD,thesyntheticprecursor
of 8-Br-N
1-cIDPR, can be easily synthesized in large quantities,
and since 8-Br-N
1-cIDPR can then be formed in high yield
chemo-enzymatically[21],weperformedthisdetailedanalysisof
cADPR-mediated Ca
2+ entry using 8-Br-N
1-cIDPR as a cADPR
agonist. The advantage of this strategy is the precise activation
of only the cADPR/RyR branch, whereas the disadvantage is that
any signalling cross-talk from other pathways triggered upon T-
cell activation that may modulate the cADPR/RyR branch is not
involved.
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Figure 9 Effect of 8-Br-N1-cIDPR on Ca2+ signalling in HEK293 cells overexpressing TRPM2
HEK-293cellstransfectedwith(a)–(c)pIRES2-EGFP-TRPM2(TRPM2)and(d)–(f)pIRES2-EGFP(EGFPcontrol)wereloadedwithFura-2AMandsubjectedtoCa2+ imaging.Timepointsofaddition
of a maximal concentration of (a and d) 100 or 300μMH 2O2,( b)a n d( e)1m M8 - B r - N1-cIDPR, or (c)a n d( f) buffer are indicated. Characteristic tracings of a representative experiment are shown.
(g) Concentration–response curve of 8-Br-N1-cIDPR in transfected HEK-293 cells (n=6–67) represented as means+ −S.E.M. of single tracings from time points 100–600s (the Ca2+ peak).
TRPM2 channel opening was described to be regulated by
ADPR, with cADPR also playing a crucial role as co-activator
[28,29]. Furthermore, co-activator effects of cADPR towards
TRPM2 aresensitive to thecADPR antagonist8-Br-cADPR [35].
Since we observed that 8-Br-cADPR effectively inhibits Ca
2+
entry evoked by 8-Br-N
1-cIDPR (Figures 8k and 8l), a contribu-
tion of TRPM2 appeared possible. To analyse this in more detail,
TRPM2 overexpressing HEK-293 cells were challenged with
8-Br-N
1-cIDPR; however, no signiﬁcant differences to control
cellswereobserved,althoughH2O2 (positivecontrol)evokedhuge
and robust TRPM2 activation. Furthermore, the direct analysis of
TRPM2 currents in patch-clamp experiments did not reveal any
evidence for activation of TRPM2 by 8-Br-N
1-cIDPR. Hence, the
previously published activation of TRPM2 by cADPR [28,35]
appears to be due to ADPR contamination, which is present
in almost all commercially available cADPR preparations (in
fact they contain up to 20% of ADPR). The preparation of
cADPR used in the experiments in the present study was further
puriﬁed to a purity of 96%; however, higher purities are very
difﬁculttoachieveduetotheinstabilityofcADPRinsolutionand
during freeze–thaw cycles. In contrast, a small effect attributable
to cADPR was observed when it was co-infused with a low
concentration of ADPR. Replacement of cADPR by 8-Br-N
1-
cIDPR in such co-infusion experiments did not evoke TRPM2
currents, suggesting that the co-activating effect of cADPR on
TRPM2 cannot be mimicked by 8-Br-N
1-cIDPR.
ActivationofOrai1/CRACM1channels(thoughnotdiscovered
at that time and thus termed capacitative Ca
2+ entry channels)
by cADPR via RyR-mediated store depletion was described
for DT40B lymphoma cells lacking expression of all three
subtypes of IP3 receptors [34]. As we did not ﬁnd evidence
for involvement of TRPM2, activation of capacitative Ca
2+
entry secondary to cADPR- or 8-Br-N
1-cIDPR-mediated store
depletion appears the most probable process involved. This
conclusion is further supported by knockdown of type 3 RyR
in T-cells, resulting in signiﬁcantly diminished sustained Ca
2+
signalling [44]. Furthermore, the sensitivity of 8-Br-N
1-cIDPR-
mediated Ca
2+ entry to SKF-96365 is also in accordance
with activation of capacitative Ca
2+ e n t r yb y8 - B r - N
1-cIDPR.
Interestingly, complete inhibition of Ca
2+ entry was observed
upon 8-Br-cADPR preincubation, whereas Ca
2+ release was only
partially inhibited. This obvious contradiction may be explained
by the non-linear activation of capacitative Ca
2+ entry by
increasing store depletion [45]. Though this effect was explained
partially by metabolism of IP3 [45], it is not unlikely that the
extent of store depletion is also not linearly coupled to activation
of capacitative Ca
2+ entry.
Taken together, we provide a detailed analysis of the mode
of action of the synthetically, easily accessible and membrane-
permeantcADPRagonist8-Br-N
1-cIDPR.As8-Br-N
1-cIDPRdid
not activate TRPM2, this cADPR analogue appears to be the ﬁrst
agonist with selectivity towards the targets RyR and TRPM2.
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Figure 10 Activation of endogenous TRPM2 currents in Jurkat T-cells by infusion of ADPR, cADPR and 8-Br-N1-cIDPR
All experiments were carried out with 2mM extracellular Ca2+ and with unbuffered intracellular Ca2+ as described in [35]. Voltage ramps from −85mV to +65mV were applied every 5s.
(a) Representative membrane current over time recorded at −80mV induced by perfusion with 300μM ADPR. (b) Representative current–voltage relationship derived from currents evoked by
voltage ramps from −85mV to +65 mV. (c) Concentration–response relationship for activation of TRPM2 currents by infusion of ADPR (, n=6–8), cADPR (, n=5–8) and 300μM
8-Br-N1-cIDPR(, n=6).Resultsrepresentmeans+ −S.E.M.ofmaximumcurrentat−80mV.(d)TRPM2currentsat−80mVafterinfusionof30μMADPR(n=8),co-infusionof5μMcADPR
and 30μMA D P R( n=9), 100μM cADPR and 30 μMA D P R( n=8), and 300μM8 - B r - N1-cIDPR and 30μMA D P R( n=6). Results represent means+ − S.E.M of maximum current at −80 mV.
(e) RP-HPLC analysis of cADPR used in the infusion experiments.
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